Oflodis

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oflodis

Property Description
Active ingredient Ofloxacin (INN)
Form Oral tablets, solutions (IV, ophthalmic, otic)
Pharmacological class Fluoroquinolone Antibiotic
Common use Resolution of bacterial infections
Origin Synthetic compound

What Type of Medicine is Oflodis? (Identity, Classification, and Origin)

Oflodis is a prescription-only medicine whose active substance is Ofloxacin, a synthetic compound classified as a second-generation fluoroquinolone. This classification places it within a family of antimicrobial drugs recognized for their broad-spectrum activity against various pathogens. Ofloxacin is a broad-spectrum antibiotic designed to control and resolve bacterial infections, such as those affecting the urinary tract or respiratory system. The substance itself is a racemate, containing the highly active L-isomer, Levofloxacin.


Composition and Available Forms of Ofloxacin (Form, Type, and Composition)

The active antimicrobial agent, Ofloxacin, is provided as a single active ingredient product in multiple dosage forms to support treatment across various infection sites. For systemic treatment, Ofloxacin is available as oral tablets and a solution for intravenous injection (parenteral administration). It is also formulated as liquid solutions for topical administration: an ophthalmic solution (eye drops) and an otic solution (ear drops). These liquid forms, stabilized using an aqueous vehicle base, allow for direct treatment of localized external infections.


The Fundamental Action of the Ofloxacin Compound (High-Level Mechanism Summary)

Ofloxacin resolves infections by exerting a bactericidal effect; it kills the bacterial organisms rather than merely suppressing their growth. This action is achieved by disrupting the bacteria's core genetic processes, specifically by inhibiting the essential enzymes DNA gyrase and topoisomerase IV. This targeted interference prevents the bacteria from successfully replicating and repairing their DNA, which is the basis for Ofloxacin's role as a broad-spectrum agent for controlling bacterial proliferation.

What side effects are possible with Oflodis?

Possible Side Effects and Safety Information

Ofloxacin is associated with adverse reactions that are classified by frequency and affected physiological system in regulatory documentation. The safety profile is structured to distinguish between common and serious events, based on official government sources (EMA, FDA).


Frequency and Common Effects

Adverse reactions that are classified as Uncommon (occurring in ge 1/1,000 to < 1/100 patients) frequently involve the Gastrointestinal and Nervous Systems. These commonly documented effects include nausea, diarrhea, abdominal pain, headache, dizziness, and insomnia. Reactions are also formally listed as Rare or Very Rare, such as severe allergic reactions or specific systemic disorders.


Documented Serious Adverse Reactions

Regulatory agencies highlight several serious and potentially irreversible effects associated with Ofloxacin and the fluoroquinolone class. These include severe Musculoskeletal and Connective Tissue Disorders like tendinitis and tendon rupture, which may occur soon after starting treatment or up to several months after stopping. Severe reactions affecting the Nervous System include peripheral neuropathy (pain, burning, weakness), convulsions, toxic psychoses, and suicidal ideation. Other serious documented risks include Aortic Aneurysm and Dissection, severe liver injury, and QT prolongation (a cardiac rhythm change).


Population-Specific Safety Considerations

Official labeling contains specific constraints for certain populations. Elderly patients are identified as having an increased risk of tendinitis and tendon rupture and increased sensitivity to cardiac effects. Systemic use is generally contraindicated in children and adolescents due to concerns about musculoskeletal toxicity (arthropathy). Caution is also noted for patients with renal impairment or those taking corticosteroid drugs, as these groups have an officially documented increased risk of tendon injury.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Oflodis (Ofloxacin) primarily targets the Central Nervous System (CNS). Documented acute manifestations include convulsions (seizures), tremors, and significant changes in mental status such as confusion, agitation, hallucinations, and paranoia. The regulatory profile also lists serious systemic outcomes, including QT interval prolongation (a serious cardiac risk), fulminant hepatitis potentially leading to liver failure, and the risk of aortic aneurysm and dissection.


Required Emergency Actions

Immediate action is mandated by official labeling. The medication must be discontinued immediately upon the first sign of a serious acute reaction. Immediate medical attention must be sought for symptoms suggesting life-threatening shock or acute vascular events. A physician in an emergency department must be consulted immediately if sudden abdominal, chest, or back pain occurs, reflecting the aortic risk.

Management for overdose is typically defined as symptomatic and supportive treatment. No specific pharmacological antidote is mentioned in regulatory documentation. For patients with pre-existing conditions, specifically severe renal impairment or those on dialysis, monitoring of serum concentration is officially required due to the risk of reduced excretion and drug accumulation.

Therapeutic Uses of Oflodis

What Oflodis Treats: Main Uses and Benefits

Oflodis is applied across domains where additional symptomatic support is needed, primarily focusing on bacterial infections that present with acute, disruptive symptom patterns. Its therapeutic application is relevant for easing symptoms associated with bacterial infections and contributes to easing the overall symptom load. The medication is indicated for a wide range of bacterial conditions.

The medication is used across conditions presenting with acute episodes in the genitourinary and major systemic tracts, including UTIs, prostatitis, pneumonia, and pelvic inflammatory disease. It may assist with addressing symptoms related to systemic imbalance and inflammatory or irritative processes. This broad application provides support that helps ease the overall symptom burden, addressing symptoms related to physical discomfort (like painful urination) and contributes to improved comfort during periods of heightened symptoms.

“It plays a role in managing symptom clusters that may become intense or disruptive, helping patients cope more steadily.”

The application is relevant in clinical settings requiring focused relief for external infections, such as bacterial conjunctivitis and specific ear infections.


Quick Fact: Supports Symptom Management for Localized and Systemic Discomfort

Regulatory References

  1. NIH StatPearls overview on Ofloxacin

Eligibility and Restrictions for Use

Oflodis (Ofloxacin) eligibility is strictly determined by official regulatory labeling, which establishes populations where the medicine is restricted or prohibited based on specific risks of the fluoroquinolone class.

Absolute Contraindications (Must Not Use)

The use of Oflodis is officially prohibited for several populations:

  • Individuals with a known hypersensitivity to Ofloxacin or any other fluoroquinolone antibacterial.
  • Pregnant women and breastfeeding women (for systemic use).
  • Children and growing adolescents (systemic use) under 18 years of age.
  • Patients with a history of tendon disorders related to previous fluoroquinolone administration.
  • Patients with a history of epilepsy or certain Central Nervous System (CNS) disorders.

Conditional Use and Restrictions

Use is allowed only with strict caution and monitoring for specific adult populations:

  • Organ Impairment: Patients with renal or hepatic impairment require close monitoring and often require formal dosage adjustment.
  • Myasthenia Gravis: Use should be officially avoided as it may exacerbate muscle weakness.
  • Cardiovascular Risk: Caution is required in patients with a known QT interval prolongation or uncorrected electrolyte imbalances.
  • Older Adults: Allowed, but with an increased labeled risk of tendinitis and tendon rupture.

What should I know about interactions with other medicines?

Oflodis Interactions with other medicines and products

Official regulatory information for Oflodis (Ofloxacin) details interactions that modify the drug's exposure or produce additive pharmacodynamic effects. The interaction profile is defined by two key constraints: the interference with absorption and the risk of combined toxicities.

Exposure-Modifying Interactions

Co-administration with metal cation-containing products—such as antacids (containing aluminum or magnesium), Sucralfate, iron supplements, and Didanosine (chewable/buffered)—results in a reduced absorption and subsequent lower serum concentration of Oflodis. To address this pharmacokinetic interaction, regulatory documents establish a mandatory timing separation requirement: oral Oflodis must be administered at least 2 hours before or 2 hours after these preparations. Furthermore, drugs that inhibit renal tubular secretion, such as Probenecid, decrease the clearance of Oflodis, resulting in officially documented increased systemic exposure.

Pharmacodynamic Interaction Risks

Official statements address interactions with agents that increase the risk of serious adverse events. Combining Oflodis with systemic corticosteroids increases the documented risk of tendinitis and tendon rupture. Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Theophylline may lead to a lowering of the cerebral seizure threshold. Oflodis may also enhance the activity of oral anticoagulants like Warfarin and increase the plasma concentration of Glibenclamide.

Mechanism of Action

Targeting Essential Bacterial DNA Enzymes

Oflodis, a fluoroquinolone, acts as an inhibitor by interacting with fundamental bacterial processes. It targets two vital bacterial enzymes: DNA gyrase and Topoisomerase IV. These enzymes are necessary for regulating the coiling of bacterial DNA during replication, transcription, and repair.


Initiating the Lethal Cascade in Bacterial Cells

The drug's mechanism initiates a cascade resulting in physiological alterations in the bacterial cell. By binding to and stabilizing the enzyme-DNA complex, Oflodis prevents the re-ligation of cleaved DNA strands. This molecular step overwhelms the bacterial cell's repair systems, causing massive, irreparable DNA fragmentation.


Resulting Bactericidal Physiological Effect

This interference with the bacterial genetic machinery leads to a bactericidal (bacteria-killing) effect. The core physiological consequence is the rapid, complete breakdown of the bacterial cell, which contributes to the elimination of the microbial population within the host system.

Dosage and Administration Information

How to Use Oflodis

Oflodis, containing the active substance Ofloxacin, is administered through several approved routes that correspond to its formulation. Systemic treatment is achieved via oral tablets or as an intravenous (IV) solution, while topical solutions are used for localized administration, specifically ophthalmic (eye drops) and otic (ear drops) uses.


Official Dosing and Administration Principles

Systemic Dosing Schedule: The standard adult systemic daily dose ranges from 200 mg to 800 mg. Dosing frequency is generally defined by the total amount: doses of 400 mg or less may be taken as a single daily dose, but daily totals exceeding 400 mg must be divided into two separate doses at equal intervals. Treatment duration varies, ranging from a 400 mg single dose for specific infections up to 6 weeks for conditions like prostatitis; systemic therapy should not exceed two months.

Intake Conditions: The oral tablets may be taken with or without food. However, absorption is significantly reduced if the tablets are taken within two hours of products containing metal ions, such as antacids, sucralfate, or iron supplements. Adequate hydration should be maintained during the course of therapy.

Dose Adjustments: Dosage adjustment is required for patients with confirmed renal impairment (reduced kidney function), where the maintenance dose must be lowered. For patients with severe hepatic impairment, the total daily systemic dose should not exceed 400 mg.

Recent Clinical Evidence

Oflodis: Recent Clinical Evidence

Overview of Treatment Approach

Research has explored a multi-modal treatment approach for chronic pain. Initial studies have monitored the time frame of symptomatic changes following administration.

Studies have examined whether the drug may be useful in managing pain. The combination of treatments was evaluated to see if it impacted outcomes.

Clinical Research Focus

1. Pain Management and Function

Research evaluated whether the combination drug was associated with changes in mobility and sleep quality. These studies primarily used patient-reported outcome measures (PROMs) to track effects over periods ranging from four to twelve weeks.

Studies have focused on populations with joint inflammation. Evidence remains limited on long-term outcomes (beyond six months) associated with this treatment, and findings were mixed regarding sustained pain reduction after treatment discontinuation.

2. Specific Symptom Subgroups

Research has explored the effects of this therapeutic option in cases of acute flare-ups. Exploratory trials also examined whether the treatment was associated with a reduction in inflammation markers.

It is not yet clear whether the drug impacts headache frequency or severity. Studies have assessed the treatment in patients also managing neuropathic pain, and evidence remains limited.

3. Scope and Tolerability Profile

The scope of research was restricted regarding patients with certain comorbidities, such as kidney conditions.

Research examined the drug’s metabolic profile and potential for drug interactions. Initial studies noted that no conclusions can be drawn regarding the drug's suitability for patients with pre-existing cardiac conditions, as this population was largely excluded from initial studies.

Key Studies & References

  1. Multimodal and interdisciplinary interventions for long term pain (Systematic Review on long-term outcomes and PROMs)
  2. Combination Drug Therapy for the Management of Chronic Neuropathic Pain (Review on specific subgroups and combination rationale)

Frequently Asked Questions (FAQ)

Common questions about Oflodis (FAQ)

Q: Is Oflodis the same type of medicine as [similar common drug name]?

A: Oflodis is classified as a fluoroquinolone antibiotic. This classification defines its chemical structure and its unique mode of action in fighting bacteria, which is distinct from many other antibiotic classes, such as penicillin or cephalosporins. According to official product information, it belongs to a specific family of antimicrobial agents.


Q: Why do people say Oflodis is a 'strong' antibiotic?

A: Oflodis is officially described as a broad-spectrum antimicrobial agent, meaning it is active against a wide variety of bacteria. Its fundamental action is bactericidal, which means it actively kills the bacteria by disrupting their core DNA processes, rather than just slowing their growth. These characteristics are the basis for its role as a broad-spectrum, bactericidal agent.


Q: Are there any common foods or drinks to avoid while using Oflodis?

A: Official information warns against taking oral Oflodis tablets at the same time as certain products containing metal ions, as this significantly reduces absorption. These include preparations like antacids, iron supplements, sucralfate, or multivitamins containing minerals. Regulatory documents describe a mandatory two-hour timing separation requirement for Oflodis and these products.


Q: How is Oflodis different from other medicines that treat similar conditions?

A: Oflodis operates by inhibiting two essential bacterial enzymes, DNA gyrase and Topoisomerase IV, which are vital for bacterial replication and repair. This distinct mechanism of action is key to its classification as a fluoroquinolone and is different from how many other antibiotic classes work. This allows it to be effective against some strains of bacteria that are resistant to other drugs.


Q: Can Oflodis cause sensitivity to the sun?

A: Yes. According to official warnings, Oflodis can make the skin more sensitive to the sun (photosensitivity). Due to this risk, the official product information recommends limiting exposure to direct sun or artificial UV light and using protective clothing.


Q: Why do some doctors choose Oflodis over other options?

A: Oflodis is chosen when an infection is known or suspected to be caused by bacteria that are susceptible to the drug. Regulatory documents describe its broad-spectrum activity as being effective against a wide range of common pathogens. Its selection is based on its demonstrated microbiological activity and its suitability for treating the specific type of infection present.


Q: Can men and women use Oflodis for the same types of conditions?

A: Oflodis is officially indicated for specific bacterial infections, such as those affecting the respiratory or urinary tract. The approved uses are based on the type of bacterial infection being treated, not the patient's gender.


Q: Does Oflodis impact the effectiveness of birth control pills?

A: Official sources generally indicate that Oflodis does not substantially reduce the effectiveness of hormonal birth control, which is a concern with some other classes of antibiotics. However, it is always recommended to check with a healthcare provider about potential interactions with specific medications.


Q: Is a metallic taste in the mouth normal when taking Oflodis?

A: The official adverse reaction lists note that some effects on the nervous and sensory systems can occur. While a metallic taste is not typically listed as a common side effect, changes in the ability to taste food have been reported in official product information.


Q: What kind of research supports the use of Oflodis for its main purpose?

A: The official uses of Oflodis are supported by clinical studies that established its safety and efficacy in treating the specific bacterial infections for which it is indicated. Furthermore, the microbiological section of the label details the proven mechanism of action, confirming its ability to inhibit bacterial DNA enzymes.


Q: Does Oflodis interact with any herbal supplements?

A: Official regulatory documents specifically list interactions with many pharmaceutical agents and metal ion-containing products (like antacids and iron). No comprehensive list of herbal supplements is provided; official documents do not rule out potential interactions with unlisted substances.


Q: Is Oflodis a high-risk medication?

A: Oflodis carries an FDA Boxed Warning (the highest level of warning) regarding the risk of serious and potentially irreversible adverse reactions. These warnings highlight the potential for disabling reactions, which include, but are not limited to, damage to tendons and nerves, and effects on the central nervous system.


Q: Can Oflodis affect blood sugar levels?

A: Yes, regulatory warnings state that Oflodis can cause disturbances in blood glucose levels. These can range from hyperglycemia (high blood sugar) to severe hypoglycemia (low blood sugar), sometimes resulting in coma. These effects mean that close monitoring may be required during treatment.


Q: Is Oflodis linked to any common skin reactions?

A: Official adverse reaction reports document skin rash as a reported side effect. Warnings also highlight the rare, but serious, risk of severe allergic and systemic skin reactions.


Q: Is the main purpose of Oflodis always to treat infections?

A: Yes. Oflodis is officially described as an antimicrobial agent, and regulatory documents state that it should be used only to treat infections. Regulatory documents state that its use is for treating or preventing infections caused by susceptible bacteria.


Q: How does Oflodis compare to older medicines in the same group?

A: Oflodis is classified as a second-generation fluoroquinolone antibiotic. Official documents note that this classification means it possesses microbiological activity against certain microorganisms. Some bacteria that may have developed resistance to older fluoroquinolones may still be susceptible to Oflodis.


Q: Do I need to change my diet while taking Oflodis?

A: Official labeling does not require a general change in diet while taking Oflodis. However, the labeling describes a required timing separation to prevent interference with absorption from metal ion-containing products, such as antacids or supplements.


Q: Are there any known issues with Oflodis and alcohol consumption?

A: Official documentation recommends that patients address the use of alcohol with a healthcare professional during treatment. This is a general caution noted because interactions between alcohol and the medicine may be possible.


Q: Is Oflodis effective against all types of bacteria?

A: No. Official documents confirm that Oflodis has activity against a wide range of bacteria, which is why it is called 'broad-spectrum.' However, its effectiveness is limited to treating organisms that are susceptible to the drug.


Q: What is the official safety classification of Oflodis?

A: Oflodis carries a US FDA Boxed Warning, which is the strongest cautionary statement for a drug regarding potentially serious health risks. The systemic drug was historically assigned an FDA Pregnancy Category C classification.


Q: Can Oflodis cause problems with vision?

A: Adverse reactions have included headache with blurred vision. The official warnings regarding central nervous system disorders note that these events, such as symptoms of increased pressure inside the skull, can sometimes include vision problems.


Q: How quickly do the side effects of Oflodis usually go away after stopping?

A: Regulatory warnings indicate that while common side effects generally resolve, certain serious adverse reactions, such as peripheral neuropathy (nerve damage), are described as being potentially permanent and may persist after the medicine is stopped.


Q: Can Oflodis interact with common pain relievers like ibuprofen?

A: Regulatory documents warn that taking Oflodis with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may increase the documented risk of lowering the cerebral seizure threshold. This interaction risk is formally stated in the official prescribing information.


Q: What does 'broad-spectrum' mean in relation to Oflodis?

A: The term broad-spectrum means that Oflodis has been shown to be active against a wide variety of bacterial microorganisms. This includes many different types of bacteria, such as both gram-negative and gram-positive organisms, as outlined in the official microbiology sections.


Q: Are there different strengths of Oflodis available?

A: Official dosing information states that the standard adult systemic daily dose ranges from 200 mg to 800 mg. This range is achieved using the available oral tablet strengths.


Q: Does Oflodis need to be taken at the exact same time every day?

A: Official dosing guidelines state that for systemic doses exceeding 400 mg, the total daily amount must be divided and taken at equal intervals. This requirement emphasizes the need for consistency in the timing of divided doses to maintain necessary drug levels in the body.


Q: Do you need a special warning about driving while taking Oflodis?

A: The official product information lists side effects such as dizziness and central nervous system effects. Official information indicates that due to these potential effects, impairment of the ability to drive or operate complex machinery has been noted.


Q: How is Oflodis eliminated from the body?

A: Official drug interaction information regarding clearance suggests that the medicine is primarily eliminated through the kidneys. This is based on regulatory warnings that show that other drugs which inhibit renal function can affect the clearance of Oflodis from the body.

How should Oflodis be stored and disposed of?

How to Store and Dispose of Oflodis?

The storage and disposal of Oflodis (Ofloxacin) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.


Official Storage Requirements

Condition Requirement
Temperature Store at room temperature, generally between 20°C and 25°C (68°F and 77°F).
Environmental Protect from light and moisture. Keep from freezing and away from excessive heat.
Packaging Keep the medicine in its original container and ensure the cap is tightly closed.
Safety It is a mandatory requirement to store Oflodis out of the sight and reach of children.

Official Disposal Instructions

Do not dispose of unused or expired Oflodis by flushing it down the toilet or pouring it into any drain or sewer system. The regulatory guidance instructs patients to utilize a local drug take-back program or consult a pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oflodis found in:

A-Z Index: